

CURRICULUM VITAE

Name: Athanasia Mouzaki

Address at work: Laboratory of Immunohematology, Division of Hematology, Dpt. of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Patras, Askliou street, Panepistimioupolis, Rion, Patras GR-26500, Greece. E-mail: mouzaki@upatras.gr

Education:

1977: High School Diploma (2nd Lyceon for Girls, Patras, GR).

1979: General Certificates of Education (GCEs) in Chemistry, Physics, Mathematics and English (Cambridge Board, UK).

1983: Bachelor's degree (B.Sc. with Honors) in Biological Sciences (Major: Physiology, Specialization: Cellular Toxicology) (University of Plymouth, UK). Diploma thesis: "Response of the lymphoid organs of the laboratory mouse to Plasmodium yoelli infection".

1985: Master's degree (MSc.) in Biological Sciences (Immunology) (University of Salford, UK). MSc thesis: "Gasterosteus aculeatus, Linnaeus: The lymphoid system, diseases and ecological correlates".

1988: Doctor of Philosophy (Ph.D.) (University of Salford, UK & Free University of Berlin, DE). Ph.D. thesis: "The rat receptor for Interleukin-2".

Positions/Teaching appointments:

1983-1985: Part-time lecturer and demonstrator, Laboratory of Immunology, University of Salford, Greater Manchester, UK.

1985-1987: Research assistant, Institute of Immunology, Medical School & Klinikum Steglitz, Berlin, DE.

1987-1990: Assistante post-doctorante, Dpt. of Molecular Biology, University of Geneva, Geneva, CH.

1991-1992: Assistante post-doctorante, Div. of Hematology, Medical School & University Hospital, Geneva, CH.

1992-1995: Maitre Assistante, Div. of Hematology, Medical School & University Hospital, Geneva, CH.

1995-1997: Lecturer of Laboratory Hematology & Transfusion Medicine, Medical School, University of Patras, Patras, GR.

1997-2003: Assistant Professor of Laboratory Hematology & Transfusion Medicine, Medical School, University of Patras, Patras, GR.

2003-2009: Associate Professor of Laboratory Hematology & Transfusion Medicine, Division of Hematology, Dpt. of Internal Medicine, Medical School, University of Patras, Patras, GR.

Current appointment: Professor of Laboratory Hematology & Transfusion Medicine, Division of Hematology, Dpt. of Internal Medicine, Medical School, University of Patras, Patras, GR. Director of the Immunohematology Laboratory.

Teaching: (1) To medical students: Main courses: The analysis and interpretation of blood tests, the lymphopoietic system, the pathogenesis of autoimmune diseases. Elective courses: Introduction to Laboratory Hematology, Immunohematology.

(2) To post-graduate students (for a Master's degree): Main courses: Research methodology, analysis of the scientific literature, how to write scientific articles. Elective courses: Immunology-clinical/cellular/molecular.

Clinical duties: Responsible for the Laboratory of the Hellenic Center for Disease Control and Prevention (KEELPNO) in Patras, Greece. The laboratory measures the HIV viral load and performs HLA-B*5701 typing and genotypic analyses to determine drug-resistance and other mutations of individuals with established HIV-1 infection attending the Division of Infectious Diseases of the University Hospital, Patras, Greece. Responsible for the investigation of the prevalence of HIV-1 subtypes in southwestern Greece.

Administrative duties: Established the research laboratory of Immunohematology and participated in the setting and start-up of common research facilities of the Medical School, University of Patras. Member (1/5) of a committee appointed by the Health Ministry to design the application of molecular testing for viruses in the Blood Centers of Greece. Member (1/3) of a committee that runs the quality control of the post-graduate course "Biomedical Sciences" of the Medical School, University of Patras. Member of the General Assembly of the Medical School, University of Patras, for the acad. years 1995-96, 1998-99, 2001-02, 2006-07, 2011-12, 2015-19. Member (since 1995) of a committee that organizes and supervises the laboratory courses of the students of the Medical School, University of Patras. Head of the committee since 2009. Vice President of the post-graduate program Medicinal Chemistry & Biological Chemistry (Dpt. of Chemistry and Medical School, University of Patras) for acad. years 2018-19 and 2019-20. Member of electoral boards for the election of faculty in Hematology and Immunology in all Greek Universities and the Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

Membership in 11 Scientific Societies. Founding member of the Hellenic Academy of Neuroimmunology.

Main research interests:

IL-2 & HIV-1:

We are studying the transcriptional regulation of the IL-2 gene and the virus HIV-1 by common trans-activating factors in naive, memory and regulatory T helper lymphocytes, with emphasis on transcriptional silencers and genomic conflict.

Hypersensitivity: Autoimmunity & Transplantation:

(1) Identification of putative errors in the transcriptional regulation of cytokine genes in T-cells from patients suffering from autoimmune diseases.

(2) Use of therapeutic peptide analogs mapping to antigenic epitopes in immunotherapy of autoimmune diseases, targeting effector T-cells and regulatory T-cells.

Generation of dendritic cell-driven tolerogenic lymphocytic responses by the use of MOG and MBP peptides for the development of personalized therapy in multiple sclerosis.

(3) Role of leptin and its receptor in autoimmune diseases.

(4) Effect of immunosuppressive drugs on regulatory T-cells and cytokines in transplant recipients.

(5) Use of therapeutic peptides in transplantation.

Viral Immunology

Effect of novel therapeutic regimens on the immune response of HSV and HPV infections

Neoplasias:

(1) Defining drug targets in multiple myeloma.

(2) Role of leptin and its receptor in hematological malignancies.

(3) Use of therapeutic peptides and dendritic cell-driven effector lymphocytic responses in immunotherapy of cancer.

(4) Role of IL-2 transcriptional silencers in the pathogenesis of cancer.

Laboratory Medicine & Transfusion Medicine

(1) Characterization of HIV-1 genetic strain diversity in experienced and naive AIDS patients in SW Greece.

(2) Effect of molecular screening for viruses in blood donations.

(3) Effect of blood transfusion on T regulatory cell populations of transfused patients undergoing elective orthopedic surgery.

Research grants - Recipient of 29 research grants (PI or co-PI). The total amount received by my laboratory from these grants = 1,253,996 €.

Supervisor of post-graduate students:

Supervisor in 16 Ph.D. Theses (12 completed), 40 MSc. theses (37 completed), 11 Diploma projects (completed). Participated in the examination committees of 53 Ph.D. theses and 16 MSc. theses.

Current members of research laboratory:

Post-doctoral scientists: 4

Post-graduate students: 7

Graduate students: 1

Scientific meetings - Participation in 114 international and national scientific meetings (invited in 78).

International Scientific Publications:

Papers: **112**

Editorials/Letters: **3**

Chapters in books: **3**

Abstracts: **137**

National Scientific Publications:

Papers: **5**

Chapters in books or proceedings volumes: **12**

Abstracts: **75**

Citations: **2,824** / h-index: **30** / i10 index: **64**

see also: <https://scholar.google.gr/citations?user=Gr9XNVMAAAAJ&hl=en&oi=ao>

IMPACT FACTORS JCR - (JOURNAL CITATION REPORTS-2018): Range = 0.96 - 70.67 / Mean = 5.22 / Cumulative = 464.62

Reviewer for:

JOURNALS: Acta Haematologica / Advances in Research / Antibodies / Archivum Immunologiae et Therapiae Experimentalis / American Journal of Physiology / Anti-Cancer Agents in Medicinal Chemistry / Bioorganic Chemistry / Blood / Blood Transfusion / BMC Hematology / BMC Immunology / BMC Research Notes / Brain Sciences / British Journal of Medicine and Medical Research / British Journal of Pharmaceutical Research / Cells / Cellular & Molecular Immunology / Clinical Immunology / Clinical Risk Management / Current Medicinal Chemistry / Current Immunology Reviews / Current Medical Literature – Multiple Sclerosis / Current Opinion in Investigational Drugs / Current Pharmaceutical Design / Cytokine / European Journal of Clinical Investigation / European Journal of Dermatology / European Journal of Neurology / European Journal of Pediatrics / Food and Chemical Toxicology / Genes and Immunity / Frontiers in Medicine / Future Neurology / Haema / Haematologica / Hormones / Immunological Investigations / ImmunoTargets and Therapy / International Aquatic Research / International Blood Research & Reviews / International Journal of Laboratory Haematology / International Journal of Medicine and Medical Sciences / International Journal of Nanomedicine / Journal of Clinical Immunology / Journal of Clinical Medicine / Journal of Hematology & Oncology / Journal of Immunology / Journal of Immunological Methods / Journal of Immunological Sciences / Journal of Medicinal Chemistry / IUBMB Life / Journal of Neuroimmunology / Journal of Neurology & Neuroimmunology / Journal of Pediatric Endocrinology and Metabolism / JSM Neurosurgery and Spine / Journal of Thrombosis and Haemostasis / Letters in Drug Design & Discovery / Medicinal Chemistry / Molecular Immunology / Neuroimmunomodulation / Pharmaceutics / PLoS ONE / Recent Patents on Inflammation & Allergy Drug Discovery / Scientific Reports / Therapeutics and Clinical Risk Management / The Open Autoimmunity Journal / The Open Immunology Journal / The Open Respiratory Medicine Journal / Transfusion Medicine and Hemotherapy / Thrombosis and Haemostasis

SCIENTIFIC BOARDS: The Netherlands Organization for Research and Development, The Health Research Board in Ireland, The Research Promotion Foundation of Cyprus, Education and Health Research Boards in Greece (IKY, KeSY, grants co-funded by the Greek government and the European Social Fund).

Guest Editor for an issue of *Current Topics in Medicinal Chemistry* (Bentham Science Publishers Ltd.). Title of issue: «Immunomodulators in Medicinal Chemistry and Drug Discovery». [Vol.6, number 16, pp.1655-1798, 2006]

Responsible for the preparation of the Greek Edition of the textbook "Lippincott's Illustrated Reviews: Immunology", 2nd Edition by T. Doan, R. Melvold, S. Viselli, C. Waltenbaugh, 2014 (ISBN: 978-960-394-985-2), which is given to 6th year medical students.

Editor-in-Chief, *The Open Immunology Journal*

Publications in international scientific journals:

1. Diamantstein T, Osawa H, Mouzaki A & Josimovic-Alasevic O. 1986. Regulation of interleukin-2 receptor expression and receptor release. *Mol. Immunol.*, 23(11):1165-1172.
2. Mouzaki A, Volk HD, Osawa H & Diamantstein T. 1987. Blocking of interleukin 2 (IL2) binding to the IL2 receptor is not required for the in vivo action of anti-IL2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL2 receptor mAb that reacts with an epitope different to the one that binds to IL2 and the mAb ART-18. *Eur. J. Immunol.*, 17(3):335-341.
3. Mouzaki A, Osawa H & Diamantstein T. 1987. An ELISA that detects cell-associated and released rat IL-2 receptors in a soluble form. *J. Immunol. Methods*, 100(1-2):243-248.
4. Mouzaki A & Diamantstein T. 1987. Four epitopes on the rat 55 kDa subunit of the interleukin 2 receptor as defined by newly developed monoclonal antibodies. *Eur. J. Immunol.*, 17(11):1661-1664.
5. Di Stefano R, Mouzaki A, Araneda D, Diamantstein T, Tilney NL & Kupiec-Weglinski JW. 1988. Anti-interleukin 2 receptor monoclonal antibodies spare phenotypically distinct T suppressor cells in vivo and exert synergistic biological effects. *J. Exp. Med.*, 167(6):1981-1986.
6. Kupiec-Weglinski JW, Hahn HJ, Kirkman L, Volk HD, Mouzaki A, Di Stefano R, Tellides G, Dallman M, Morris PJ, Strom TB, Tilney NL & Diamantstein T. 1988. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy. *Transplantat. Proc.*, 20(2):207-216.
7. Stünkel KG, Theisen P, Mouzaki A, Diamantstein T & Schlumberger HD. 1988. Monitoring of interleukin-2 receptor (IL-2R) expression in vivo and studies on an IL-2R-directed immunosuppressive therapy of active and adoptive adjuvant-induced arthritis in rats. *Immunology*, 64(4):683-689.
8. Diamantstein T, Mouzaki A, Osawa H, Volk HD, Hahn HJ, Kirkman RL, Strom TB, Tilney NL & Kupiec-Weglinski JW. 1988. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL2R)-targeted immunotherapy. The action of anti-IL2R monoclonal antibodies and synergistic effect of cyclosporin A. *Dev. Biol. Stand.*, 69:177-184.
9. Herrmann T, Josimovic-Alasevic O, Mouzaki A & Diamantstein T. 1989. Demonstration of two distinct forms of the released low affinity type rat interleukin 2 receptor. *Immunology*, 66(3):384-387.
10. Bartok I, Erdei A, Mouzaki A, Osawa H, Szolosi J, Eigentler A, Diamantstein T, Dierich M & Gergely J. 1989. Interaction between C3 and IL-2; inhibition of C3b binding to CR1 by IL-2. *Immunol. Letters*, 21(2):131-137.
11. Mouzaki A, Weil R, Muster L & Rungger D. 1991. Silencing and trans-activation of the mouse IL-2 gene in *Xenopus* oocytes by proteins from resting and mitogen-induced primary T-lymphocytes. *EMBO J.*, 10(6):1399-1406.
12. Tucci A, Mouzaki A, James H, Bonnefoy J-Y & Zubler RH. 1991. Are cord blood B cells functionally mature? *Clin. Exp. Immunol.*, 84(3):389-394.
13. Mouzaki A, Zubler RH, Doucet A & Rungger D. 1992. Trans-active factors controlling the IL-2 gene in adult human T-cell subsets. *Mediat. Inflamm.*, 1(1):33-37.

14. Mouzaki A, Dai Y, Weil R & Rungger D. 1992. Cyclosporin A and FK506 prevent the derepression of the IL-2 gene in mitogen-induced primary T lymphocytes. *Cytokine*, 4(2):151-160.
15. Hentsch B, Mouzaki A, Pfeuffer I, Rungger D & Serfling E. 1992. The weak, fine-tuned binding of ubiquitous transcription factors to the IL-2 enhancer contributes to its T cell-restricted activity. *Nucleic Acids Res.*, 20(11):2657-2665.
16. Mouzaki A, Rungger D, Tucci A, Doucet A & Zubler RH. 1993. Occurrence of a silencer for the interleukin-2 gene in naïve but not memory resting T helper cells. *Eur. J. Immunol.* 23(7):1469-1474.
17. Mouzaki A & Rungger D. 1994. Interleukin 2 gene regulation at the P_{ud} (NFAT) promoter element: The complex situation in primary T lymphocytes. *Proc. Molec. Biol. Hematopoiesis*, 3:475-486.
18. Mouzaki A & Rungger D. 1994. Properties of transcription factors regulating interleukin 2 gene transcription through the NFAT binding site in untreated or drug-treated naïve and memory T helper cells. *Blood*, 84(8):2612-2621.
19. Mouzaki A & Zubler RH. 1995. Regulation de la transcription du gene de l'interleukine-2 dans les lymphocytes B. *Swiss Med. Wkly*, 125(9):395-399.
20. Mouzaki A, Serfling E & Zubler RH. 1995. Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor- κ B. *Eur. J. Immunol.*, 25(8):2177-2182.
21. Mouzaki A, Matthes T, Miescher PA & Beris P. 1995. Polyclonal hypergammaglobulinaemia in a case of B cell Chronic Lymphocytic Leukaemia: The result of IL-2 production by the proliferating monoclonal B cells? *Br. J. Haematol.*, 91(2):345-349.
22. Mouzaki A, Kindler V, Browers N, Doucet A, Melachrinou M, Kyrtsionis M-C & Kallinikou-Maniatis A. 1996. Cytokine gene expression in a case of B-cell Chronic Lymphocytic Leukaemia (B-CLL) with an unusual expansion of T cells at presentation. *Proc. Molec. Biol. Hematopoiesis*, 5:237-246.
23. Kyrtsionis M-C, Repa C, Dedoussis GVZ, Mouzaki A, Simeonidis A, Stamatelou M & Maniatis A. 1998. Serum transforming growth factor- β 1 (TGF- β 1) in patients with multiple myeloma (MM). *Med. Oncol.*, 15(2):124-128.
24. Mouzaki A, Dionyssopoulou H, Sotiropoulou G, Cordopatis P, Slootstra J, Puijk W, Meloen R & Maniatis A. 1999. Synthetic peptides as putative therapeutic agents in transplantation medicine: Identification of epitopes on the extra cellular domain of the beta chain of the interleukin-2 receptor. *Biomed. & Health Res. Ser.*, 22:181-193.
25. Dedoussis GVZ, Mouzaki A, Theodoropoulou M, Menounos P, Kyrtsionis M-C, Karameris A & Maniatis A. 1999. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line. *Exp. Cell Res.*, 249(2):269-278.
26. Kyrtsionis M-C, Mouzaki A & Maniatis A. 1999. Mechanisms of polyclonal hypogammaglobulinemia in multiple myeloma. *Med. Oncol.*, 16(2):73-77.
27. Dionyssopoulou E, Mouzaki A, Slootstra J, Puijk W, Meloen R, Cordopatis R & Sotiropoulou G. 2000. Synthetic peptides as putative therapeutic agents in transplantation medicine: Application of PEPSCAN to the identification of functional sequences on the extracellular domain of the Interleukin-2 receptor beta chain (IL-2R β). *J. Immunol. Methods*, 241(1-2):83-95.
28. Mouzaki A, Doucet A, Mavroidis E, Muster L & Rungger D. 2000. A repression-derepression mechanism regulating the transcription of human immunodeficiency virus type 1 in primary T cells. *Mol. Med.*, 6(5):377-390.
29. Karakantza M, Mouzaki A, Theodoropoulou M, Bussel JB & Maniatis A. 2000. Th1 and Th2 cytokines in a patient with Evans' syndrome and profound lymphopenia. *Br. J. Haematol.*, 110(4):968-970.
30. Tselios T, Daliani I, Deraos S, Thymianou S, Matsoukas E, Troganis A, Gerothanassis I, Mouzaki A, Mavromoustakos T, Probert L & Matsoukas I. 2000. Treatment of experimental allergic encephalomyelitis (EAE) by a rationally designed cyclic analogue of myelin basic protein (MBP) epitope 72-85. *Bioorg. Med. Chem. Lett.*, 10(24):2713-2717.
31. Theodoropoulou M, Karakantza M, Maniatis A & Mouzaki A. 2000. Cytokine gene expression in a case of Evan's syndrome. *Proc. Eur. Fed. Immunol. Soc.*, 1:287-293.

32. Leotsinidis M, Theodoropoulou M, Alexopoulos A, Chatzantoni K, Farri-Kostopoulou E & Mouzaki A. 2000. Leptin and interleukin-2 in babies. *Proc. Eur. Fed. Immunol. Soc.*, 1:281-285.
33. Doucet A & Mouzaki A. 2000. HIV-1 regulation in peripheral blood T-cells. *Proc. Eur. Fed. Immunol. Soc.*, 1:385-391.
34. Xagoraris I, Zikos P, Karakantza M, Maniatis A & Mouzaki A. 2000. Apoptosis in multiple myeloma cells. *Proc. Eur. Fed. Immunol. Soc.*, 1:113-119.
35. Xagoraris I, Paterakis G, Zolota B, Zikos P, Maniatis A & Mouzaki A. 2001. Expression of granzyme B and perforin in multiple myeloma. *Acta Haematol.*, 105(3):125-129.
36. Kakkos SK, Mouzaki A & Vagianos CE. 2001. Modifications of the immune system caused by the cestode *Echinococcus granulosus*. *Ann. Gastroenterol.*, 14(2):91-98.
37. Tselios T, Apostolopoulos V, Daliani I, Deraos S, Grdadolnik S, Mavromoustakos T, Melachrinou M, Thymianou S, Probert L, Mouzaki A & Matsoukas I. 2002. Antagonistic effects of human MBP₈₇₋₉₉ altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. *J. Med. Chem.*, 45(2):275-283.
38. Thymianou S, Chatzantoni K, Karakantza M, Tselios T, Papathanassopoulos P, Matsoukas JM & Mouzaki A. 2002. Effect of linear and cyclic peptide analogues of myelin basic epitope MBP72-85 on human T-cell activation. *Biomed. & Health Res.*, 55:241-250.
39. Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis M-C & Maniatis A. 2002. Expression Patterns of Th1 and Th2 Cytokine Genes in Childhood Idiopathic Thrombocytopenic Purpura (ITP) at Presentation and their Modulation by Intravenous Immunoglobulin G (IVIg) Treatment; their Role in Prognosis. *Blood*, 100(5):1774-1779.
40. Panitsas F, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou G, Zoumbos NC, Maniatis A & Mouzaki A. 2004. Adult chronic idiopathic thrombocytopenia purpura (ITP) is the manifestation of a type-1 polarized immune response. *Blood*, 103(7):2645-2647.
41. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F & Gogos CA. 2004. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. *Clin. Diagn. Lab. Immunol.*, 11(1):161-167.
42. Argyropoulos C, Nikiforidis GC, Theodoropoulou M, Adamopoulos P, Boubali S, Georgakopoulos TN, Paliogianni F, Papavassiliou AG & Mouzaki A. 2004. Mining microarray data to identify transcription factors expressed in naïve resting but not activated T lymphocytes. *Genes Immun.*, 5(1):16-25.
43. Karakantza M, Theodorou GL, Mouzaki A, Theodori E, Vagianos C & Maniatis A. 2004. In vitro study of the long-term effects of post traumatic splenectomy on cellular immunity. *Scand. J. Immunol.*, 59(2):209-219.
44. Chatzantoni K, Thymianou S, Papathanassopoulos P, Tselios T, Kalbacher H, Matsoukas J & Mouzaki A. 2004. Immunological profile of myelin basic protein (MBP) peptides. In: «Immunology 2004», pp.171-175, Medimond, Bologna (Italy). [www.medimond.com]
45. Argyropoulos C, Adamopoulos P, Georgakopoulos T, Chatzantoni K, Nikiforidis G & Mouzaki A. 2004. Identification of transcriptional repressors of HIV virus in naïve T lymphocytes using «wet» bioinformatics techniques. In: «Immunology 2004», pp.267-271, Medimond, Bologna (Italy). [www.medimond.com]
46. Chatzantoni K, Papathanassopoulos P, Gourzoulidou E & Mouzaki A. 2004. Leptin and its soluble receptor in plasma of patients suffering from remitting-relapsing multiple sclerosis (MS). In vitro effects of leptin on type-1 and type-2 cytokine secretion by peripheral blood mononuclear cells, T-cells and monocytes of MS patients. *J. Autoimmun.*, 23(2):169-177.
47. Parissi T, Chatzantoni K, Deraos S, Matsoukas I & Mouzaki A. 2004. Synthetic peptides mapping to epitopes of the extracellular domain of the IL-2 receptor (IL-2R) beta chain to inhibit T-cell activation. *Transplant. Proc.*, 36(6):1723-1727.
48. Mouzaki A, Tselios T, Papathanassopoulos P, Matsoukas I & Chatzantoni K. 2004. Immunotherapy for Multiple Sclerosis: Basic insights for new clinical strategies. *Curr. Neurovasc. Res.*, 1(4):325-340.
49. Karakantza M, Theodorou GL, Meimaris N, Mouzaki A, Ellul J, Andonopoulos AP & Maniatis A. 2004. Type-1 and Type-2 Cytokine-producing CD4+ and CD8+ Cells in Primary Antiphospholipid Syndrome (PAPS). *Ann. Hematol.*, 83(11):704-711.

50. Micheva I, Thanopoulou E, Michalopoulou S, Karakantza M, Kouraklis-Symeonidis A, Mouzaki A & Zoumbos N. 2004. Defective tumor necrosis factor alpha-induced maturation of monocyte-derived dendritic cells in patients with myelodysplastic syndromes. *Clin. Immunol.*, 113(3):310-317.
51. Panitsas FP & Mouzaki A. 2004. Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP). *BMC Blood Disord.*, 4(1):4, pp.1-5 [<http://www.biomedcentral.com/1471-2326/4/4>] // PubMed]
52. Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, Mouzaki A & Kalofonos HP. 2004. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. *Oncology*, 67(2):179-182.
53. Matsoukas J, Apostolopoulos V, Kalbacher H, Papini A-M, Tselios T, Chatzantoni K, Biagioli T, Lolli F, Deraos S, Papathanassopoulos P, Troganis A, Mantzourani E, Mavromoustakos T & Mouzaki A. 2005. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: Enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. *J. Med. Chem.*, 48(5):1470-1480.
54. Mouzaki A, Deraos S & Chatzantoni K. 2005. Advances in the treatment of autoimmune diseases; cellular activity, type-1/type-2 cytokine secretion patterns, and their modulation by therapeutic peptides. *Curr. Med. Chem.*, 12(13):1537-1550.
55. Mouzaki A. 2006. *Curr. Top. Med. Chem.*, 6(16):1655. [EDITORIAL]
56. Chatzantoni K & Mouzaki A. 2006. Anti-TNF-a antibody therapies in autoimmune diseases. *Curr. Top. Med. Chem.*, 6(16):1707-1714.
57. Argyropoulos C & Mouzaki A. 2006. Immunosuppressive drugs in HIV disease. *Curr. Top. Med. Chem.*, 6(16):1769-1789.
58. Michalopoulou S, Micheva I, Karakantza M, Kouraklis-Symeonidis A, Mouzaki A & Zoumbos NC. 2006. Enhanced expression and inducibility of cytoprotective Heat Shock Proteins (Hsps) in the bone marrow of patients with Myelodysplastic Syndrome (MDS): correlation with disease progression. *Haematologica*, 91(12):1714-1716.
59. Leonidou L, Mouzaki A, Michalaki M, de Lastic AL, Kyriazopoulou V, Bassaris HP & Gogos CA. 2007. Cytokine production and hospital mortality in patients with sepsis-induced stress hyperglycemia. *J. Infect.*, 55(4):340-346.
60. Theodorou GL, Mouzaki A, Tsiftsis D, Apostolopoulou A, Mougou A, Theodori E, Vagianos C & Karakantza M. 2007. Effect of non-operative management (NOM) of splenic rupture versus splenectomy on the distribution of peripheral blood lymphocyte populations and cytokine production by T cells. *Clin. Exp. Immunol.*, 150(3):429-436.
61. Sgourou A, Karakantza M, Theodori E, Papadimitriou C, Theodorou GL, Davanos N, Thymianou S, Zoumbos NC & Mouzaki A. 2008. Procleix Ultrio transcription mediated amplification (TMA) vs serologic blood screening in southwestern Greece. *Transfus. Med.*, 18(2):104-111. [doi: 10.1111/j.1365-3148.2008.00847.x]
62. Theodorou GL, Marousi S, Ellul J, Mougou A, Theodori E, Mouzaki A & Karakantza M. 2008. Th1/Th2 cytokine expression shift in peripheral blood CD4+ and CD8+ T-cells of patients at the post-acute phase of stroke. *Clin. Exp. Immunol.*, 152(3):456-463. [doi: 10.1111/j.1365-2249.2008.03650.x]
63. Fourtounas C, Mouzaki A & Vlachojannis JG. 2008. Desensitization during renal transplantation. *NEJM*, 359(16):1731. [Scientific Correspondence] [doi: 10.1056/NEJMc081723]
64. Papanastasiou AD, Chatzantoni K & Mouzaki A. 2008. Current therapeutic leads for the treatment of autoimmune diseases: stem cell transplantation and inhibition of post-translational modifications of auto-antigens. *Exp. Opin. Drug Disc.*, 3(10):1255-1265. [doi: 10.1517/17460441.3.10.1255]
65. Deraos G, Chatzantoni K, Matsoukas M-T, Tselios T, Deraos S, Katsara M, Papathanasopoulos P, Vynios D, *Apostolopoulos V, *Mouzaki A, *Matsoukas J. 2008. Citrullination of linear and cyclic altered peptide ligands from Myelin Basic Protein (MBP87-99) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease. *J. Med. Chem.*, 51(24):7834-7842. [doi: 10.1021/jm800891n] [*senior authors]
66. Charokopos N, Apostolopoulos N, Kalapodi M, Leotsinidis M, Karamanos N & Mouzaki A. 2009. Bronchial asthma, chronic obstructive pulmonary disease and NF-kB. *Curr. Med. Chem.*, 16(7): 867-883.

67. Mania VM, Kallivokas AG, Malavaki C, Asimakopoulou AP, Kanakis J, Theocharis AD, Klironomos G, Gatzounis G, Mouzaki A, Panagiotopoulos E & Karamanos NK. 2009. A comparative biochemical analysis of glycosaminoglycans and proteoglycans in human orthotopic and heterotopic bone. *IUBMB Life*, 61(4):447-452. [doi: 10.1002/iub.167]
68. Katsoulidou A, Paraskevis D, Magiorkinis E, Moschidis Z, Haida C, Hatzitheodorou E, Varaklioti A, Karafoulidou A, Hatzitaki M, Kavallierou L, Mouzaki A, Andrioti E, Veneti C, Kaperoni A, Zervou E, Politis C & Hatzakis A. 2009. Molecular characterization of occult hepatitis B cases in Greek blood donors. *J. Med. Virol.*, 81(5):815-825. [doi: 10.1002/jmv.21499]
69. Mouzaki A, Panagoulas I, Dervilli Z, Zolota V, Spadidea P, Rodi M, Panitsas FP, Lagadinou E, de Lastic A-L & Georgakopoulos T. 2009. Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells. *Cytokine*, 48(3):203-211. [doi: 10.1016/j.cyto.2009.07.006]
70. Kyrtonis M-C, Maltezas D, Koulieris E, Zaroulis C, Tzenou T, Sachanas S, Bartzis V, Georgiou G, Dimou M, Siakavellas S, Vassilakopoulos TP, Angelopoulou MK, Koutra E, Mouzaki A, Pangalis GA & Panayiotidis P. 2010. Response to Bortezomib in refractory/relapsed multiple myeloma patients: A single center experience with discussion on specific issues. *APJOH*, 2(1):29-39.
71. Stoukas VS, Prousalis KP, Panagoulas I, Zarkadis IK & Mouzaki A. 2010. Postmortem redistribution of phenobarbital in a rat model. *Can. Soc. Forensic Sci. J.*, 43(1):1-8.
72. Fourtounas C, Dousdampanis P, Sakellarakis P, Rodi M, Georgakopoulos T, Vlachojannis JG & Mouzaki A. 2010. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients. *Am. J. Nephrol.*, 32(1):1-9. [doi: 10.1159/000313940]
73. Mouzaki A, Koutsokera M, Dervilli Z, Rodi M, Kalavrizioti D, Dimisianos N, Matsoukas I & Papathanasopoulos P. 2010. Remitting-relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab. *Int. J. Gen. Med.*, 3:313-320. [doi: 10.2147/IJGM.S13648]
74. Tsambaos D, Rodi M, Pasmatzis E, Monastirli A, Papadaki H & Mouzaki A. 2011. Long-term Remission of Recurrent Herpes Labialis Following Topical Imiquimod Application on Distant Healthy Skin: A Clinical and Immunological Study. *Antivir. Ther.* 16(6):863-869. [doi: 10.3851/IMP1793]
75. Dimitrakopoulos F-ID, Papadaki H, Antonacopoulou AG, Kottorou A, Gotsis AD, Scopa C, Kalofonos HP & Mouzaki A. 2011. Association of FoxP3 expression with non-small cell lung cancer. *Anticancer Res.*, 31(5):1677-1683.
76. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Korantzopoulos P & Tsianos EV. 2011. Serum IL-6 levels and cirrhosis-associated pulmonary hypertension. *Angiology*, 62(4):344-345. [doi: 10.1177/0003319710396352]
77. Kalambokis GN, Mouzaki A, Rodi M, Pappas K & Tsianos EV. 2011. Bacterial translocation attenuates the systemic hemodynamic improvement produced by Terlipressin in patients with cirrhosis. *Hepatology*, 54(2):743-744. [doi: 10.1002/hep.24424]
78. Dimitropoulou D, Karanantza M, Tsamandas AC, Mouzaki A, Theodorou G & Gogos CA. 2011. T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic Hepatitis B and C. *In Vivo*, 25(5):833-840.
79. Kalambokis GN, Mouzaki A, Rodi M & Tsianos EV. 2012. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. *Liver Int.*, 32(3):467-475. [doi: 10.1111/j.1478-3231.2011.02650.x]
80. Varvarigou AA, Thomas I, Rodi M, Economou I, Mantagos S & Mouzaki A. 2012. Respiratory distress syndrome (RDS) in premature infants is underscored by the magnitude of Th1 cytokine polarization. *Cytokine*, 58(3):355-360. [doi: 10.1016/j.cyto.2012.03.005]
81. Kalambokis GN, Mouzaki A, Rodi M & Tsianos EV. 2012. Rifaximin for the prevention of spontaneous bacterial peritonitis. *World J. Gastroenterol.*, 18(14):1700-1702. [doi: 10.3748/wjg.v18.i14.1700]
82. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Korantzopoulos P & Tsianos EV. 2012. Circulating endotoxin and interleukin-6 levels are associated with Doppler-evaluated pulmonary vascular resistance in cirrhotic patients. *Hepatol. Int.*, 6(4):783-789. [doi: 10.1007/s12072-011-9337-0]

83. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X & Tsianos EV. 2012. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. *Clin. Gastroenterol. Hepatol.*, 10(7):815-818. [doi: 10.1016/j.cgh.2012.02.025]
84. Mouzaki A, Panagoulas I, Raptis G & Farri-Kostopoulou E. 2012. Cord blood leptin levels of healthy neonates are associated with IFN-g production by cord blood T-cells. *PLoS ONE*, 7(7):e40830. [http://dx.doi.org/10.1371/journal.pone.0040830]
85. Dimitropoulou D, Karakantza M, Theodorou GL, Leonidou L, Assimakopoulos SF, Mouzaki A & Gogos CA. 2013. Serum cytokine profile in patients with hepatitis B e antigen-negative chronic active hepatitis B and inactive hepatitis B virus carriers. *World J. Gastrointest. Pathophysiol.*, 4(1):24-27. [doi: 10.4291/wjgp.v4.i1.24]
86. de Lastic A, Rodi M & Mouzaki A. 2013. Th1/Th2/Th17 profile and T cell phenotype of an in vitro antigen presentation system in response to DC functionality, IL-2 and IGF-1 presence. In: «Immunology 2013», pp.17-19 [www.medimond.com]
87. Lagadinou M, Solomou EE, Mouzaki A & Gogos CA. 2014. Alterations in cytokine measurements in ascitic fluid of cirrhotic patients with and without spontaneous bacterial peritonitis. *Clin. Hepatol. Hepat. Rep.*, 2014(1):1-4. [http://dx.doi.org/10.7243/2055-088X-1-1].
88. Lekkou A, Mouzaki A, Siagris D, Ravani I & Gogos CA. 2014. Serum lipid profile, cytokine production and clinical outcome in patients with severe sepsis. *J. Crit. Care*, 29:723-727. [doi: 10.1016/j.jcrc.2014.04.018]
89. Kostopoulou ON, Kouvela EC, Magoulas GE, Garnelis T, Panagoulas I, Rodi M, Papadopoulos G, Mouzaki A, Dinos GP, Papaioannou D & Kalpaxis DL. 2014. Conjugation with polyamines enhances the antibacterial and anticancer activity of chloramphenicol. *Nucleic Acids Res.*, 42(13):8621-8634. [doi: 10.1093/nar/gku539]
90. Dimisianos N, Rodi M, Kalavrizioti D, Georgiou LV, Papatheanasopoulos P & Mouzaki A. 2014. Cytokines as Biomarkers of Multiple Sclerosis Disease Progression and Treatment Response to IFN β . *Mult. Scler. Int.*, art. ID 436764. [http://dx.doi.org/10.1155/2014/436764].
91. Sazakli E, Villanueva CM, Kogevinas M, Maltezis K, Mouzaki A, Leotsinidis M. 2014. Chromium in drinking water: Association with biomarkers of exposure and effect. *Int. J. Environ. Res. Public Health*, 11(10):10125-10145. [doi: 10.3390/ijerph110x0000x].
92. Mouzaki A. 2015. Stem cell transplantation (SCT) to treat severe refractory multiple sclerosis (MS). *Int. J. Transplant. Res. Med.*, 1:002e. [EDITORIAL] [http://clinmedjournals.org/articles/ijtrm/ijtrm-1-002e.pdf].
93. Deraos G, Rodi M, Kalbacher H, Chatzantoni K, Karagiannis F, Synodinos L, Plotas P, Papalois A, Dimisianos N, Papatheanasopoulos P, Gatos D, Tselios T, Apostolopoulos V, Mouzaki A*, Matsoukas J*. 2015. Properties of myelin altered peptide ligand cyclo(87-99)(Ala91,Ala96)MBP87-99 render it a promising drug lead for immunotherapy of Multiple Sclerosis. *Eur. J. Med. Chem.*, 101:13-23. [doi: 10.1016/j.ejmech.2015.06.015] [*senior authors]
94. Kostopoulou ON, Magoulas GE, Papadopoulos GE, Mouzaki A, Dinos GP, Papaioannou D & Kalpaxis DL. 2015. Synthesis and evaluation of chloramphenicol homodimers: Molecular target, antimicrobial activity, and toxicity against human cells. *PLoS ONE*, 10(8):e0134526. [doi: 10.1371/journal.pone.0134526]
95. Mouzaki A, Rodi M, Dimisianos N, Emmanuil A, Kalavrizioti D, Lagoudaki R, Nikolaos C. Grigoriadis NC & Papatheanasopoulos P. 2015. Immune parameters that distinguish multiple sclerosis patients from patients with other neurological disorders at presentation. *PLoS ONE*, 10(8):e0135434. [doi: 10.1371/journal.pone.0135434]
96. Mouzaki A, Garyfallou MI, Chatzantoni K. Stem cell transplantation to treat severe refractory multiple sclerosis. 2015. *Int. J. Transplant. Res. Med.*, 1:008, pp. 1-3. [http://clinmedjournals.org/articles/ijtrm/int-j-transplant-res-med-1-008.pdf].
97. Kalavrizioti D, Gerolymos M, Rodi M, Kalliakmani P, Provatopoulou S, Eleftheriadis T, Mouzaki A, Goumenos D. 2015. T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: can they predict outcome? *Cytokine*, 76(2):260-269. [doi: 10.1016/j.cyto.2015.08.002]
98. Davanos N, Panos G, Gogos CA & Mouzaki A. 2015. HIV-1 subtype characteristics of infected persons living in southwestern Greece. *HIV/AIDS-Res. Palliat. Care*, 7:277-283. *HIV AIDS (Auckl)*, 7:277-283. [doi: 10.2147/HIV.S90755.]

99. de Lastic A-L, Rodi M & Mouzaki A. 2016. Effect of dendritic cell state and antigen-presentation conditions on resulting T-cell phenotypes and Th cytokine profiles. *Immunobiology*, 221(8):862-870. [doi: 10.1016/j.imbio.2016.04.001]
100. Rodi M, Dimisianos N, de Lastic A-L, Sakellaraki P, Deraos G, Matsoukas J, Papathanasopoulos P & Mouzaki A. 2016. Regulatory cell populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens. *Int. J. Mol. Sci.*, 17(9):1398, pp.1-17. [doi: 10.3390/ijms17091398].
101. Aggelakopoulou M, Kourepini E, Paschalidis N, Simoes DCM, Kalavrizioti D, Dimisianos N, Papathanasopoulos P, Mouzaki A, Panoutsakopoulou V. 2016. ER β -dependent direct suppression of human and murine Th17 cells and treatment of established central nervous system autoimmunity by a neurosteroid. *J. Immunol.*, 197(7):2598-2609. [doi: 10.4049/jimmunol.1601038]
102. Dousdampanis P, Trigka K & Mouzaki A. 2016. Tregs and Kidney: from Diabetic Nephropathy to Renal Transplantation. *World J. Transplant.*, 6(3):556-563. [doi: 10.5500/wjt.v6.i3.556]
103. Tsvigoulis G, Katsanos AH, Mavridis D, Grigoriadis N, Dardiotis E, Heliopoulos I, Papathanasopoulos P, Karapanayiotides T, Kilidireas C, Hadjigeorgiou GM, Voumvourakis K, HELANI (Gravanis A, Papadimitriou A, Rompos A, Mouzaki A, Karagogeos D, Kollias G, Probert L, Ioannidis P, Pelidou S-E, Tzartos S, Panoutsakopoulou V). 2016. The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized-Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials. *PLoS ONE* 11(9): e0163296. [doi: 10.1371/journal.pone.0163296].
104. Panagoulas I, Georgakopoulos T, Aggeletopoulou I, Agelopoulos M, Thanos D & Mouzaki A. 2016. Transcription Factor Ets-2 Acts as a Pre-induction Repressor of Interleukin-2 (IL-2) Transcription in Naive T Helper Lymphocytes. *J. Biol. Chem.*, 291(52):26707-26721. [doi: 10.1074/jbc.M116.762179]
105. Triantos C, Kalafateli M, Spadidea PI, Goukos D, Koutroumpakis E, Konstantakis C, Assimakopoulos SF, Gogos C, Mouzaki A, Daikos G, Thomopoulos K. 2017. Bacterial load and cytokine profile in patients with cirrhosis following therapy with proton pump inhibitors: a prospective cohort study. *Ann. Gastroenterol.*, 30(4):450-456. [doi: 10.20524/aog.2017.0142].
106. Yannakakis M-P, Simal C, Tzoupis H, Rodi M, Dargaji N, Prakash M, Mouzaki A, Platts JA, Apostolopoulos V, Tselios TV. 2017. Design and synthesis of non-peptide mimetics mapping the immunodominant myelin basic protein (MBP₈₃₋₉₆) epitope to function as T-cell receptor antagonists. *Int. J. Mol. Sci.*, 18(6):1215, pp.1-29. [doi: 10.3390/ijms18061215].
107. Panagoulas I, Karagiannis F, Aggeletopoulou I, Georgakopoulos T, Argyropoulos CP, Akinosoglou K, Gogos C, Skoutelis A & Mouzaki A. 2018. Ets-2 acts as a transcriptional repressor of the human immunodeficiency virus type 1 through binding to a repressor-activator target sequence of 5'-LTR. *Front. Immunol.*, 8(JAN):1924, pp.1-15. [doi: 10.3389/fimmu.2017.01924].
108. Toumpeki C, Anastasakis D, Panagoulas I, Stamatopoulou V, Georgakopoulos T, Kallia-Raftopoulos S, Mouzaki A*, Drinas D*. 2018. Construction of an M1GS ribozyme for targeted and rapid mRNA cleavage; application on the Ets-2 oncogene. *Med. Chem.*, 14(6):604-616. [doi: 10.2174/1573406414666180112115201] / [*senior authors]
109. Stravodimou A, Tzelepi V, Papadaki H, Mouzaki A, Georgiou S, Melachrinou M, Kourea EP. 2018. Evaluation of T lymphocyte subpopulations in Actinic Keratosis, In Situ and Invasive Squamous Cell Carcinoma of the Skin. *J. Cutan. Pathol.*, 45(5):337-347. [doi: 10.1111/cup.13123]
110. Psianou K, Panagoulas I, Papanastasiou AD, de Lastic A-L, Rodi M, Spantidea PI, Degn SE, Georgiou P & Mouzaki A. 2018. Clinical and immunological parameters of Sjögren's syndrome. *Autoimmun. Rev.*, 17(10):1053-1064. [doi: 10.1016/j.autrev.2018.05.005]
111. Triantos C, Aggeletopoulou I, Kalafateli M, Spantidea PI, Vourli G, Diamantopoulou G, Tapratzi D, Michalaki M, Manolakopoulos S, Gogos C, Kyriazopoulou V, Mouzaki A, Thomopoulos K. 2018. Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis. *Sci. Rep.*, 8(1):14065. [doi: 10.1038/s41598-018-32482-3]
112. Gioldasi S, Karvela A, Rojas-Gil AP, Rodi M, de Lastic A-L, Thomas I, Spiliotis BE & Mouzaki A. 2019. Metabolic association between leptin and the corticotropin releasing hormone. *Endocr. Metab. Immune Disord. Drug Targets*, 19(4):458-466. [doi: 10.2174/1871530319666190206165626]

113. Marazioti A, Papadia K, Kannavou M, Spella M, Basta A, de Lastic A-L, Rodi M, Mouzaki A, Samiotaki M, Panayotou G, Stathopoulos GT, Antimisiaris S. 2019. Cellular Vesicles: New insights in engineering methods, interaction with cells and potential for brain targeting. *J. Pharmacol. Exp. Ther.*, 370(3):772-785. [doi: <https://doi.org/10.1124/jpet.119.257097>]
114. Triantos C, Kalafateli M, Aggeletopoulou I, Diamantopoulou G, Spantidea PI, Michalaki M, Vourli G, Manolakopoulos S, Gogos C, Kyriazopoulou V, Mouzaki A, Thomopoulos K. Vitamin D related immunomodulation in patients with liver cirrhosis. *Eur. J. Gastroenterol. Hepatol.*, (in press).
115. Stravodimou A, Tzelepi V, Balasis S, Georgiou S, Papadaki H, Mouzaki A, Melachrinou M, Kourea EP. PD-L1 expression, T lymphocyte subpopulations and Langerhans Cells in cutaneous Invasive Squamous Cell Carcinoma and Precursor Lesions. *Cancer Immunol. Immunother.*, (under minor revision).

Chapters in Books

- Mouzaki A, Kupiec-Weglinski JW, Volk HD & Diamantstein T. 1989. In vivo action of anti-interleukin 2 receptor monoclonal antibodies. In: «Cellular Basis of Immune Modulation», pp.547-550, JG Kaplan & DR Green (Eds.), AR Liss Inc., New York.
- Chatzantoni K & Mouzaki A. 2009. Immunomodulation in the nervous and vascular systems during inflammation and autoimmunity; the role of T regulatory cells. In: “Neurovascular Medicine: Pursuing Cellular Longevity for Healthy Aging”, K. Maiese (Ed.), Oxford University Press, New York. Chapter 14, pp. 345-366.
- Chatzantoni K & Mouzaki A. 2010. Stem cell transplantation to treat severe refractory autoimmune diseases. In: “New Insights in Hematopoietic Cell Transplantation”, A. Spyridonidis & I. Sakellari (Eds.), Research Signpost, Kerala. Chapter 15, pp. 271-284.